236 related articles for article (PubMed ID: 17845136)
21. Recombinant activated factor VII as a universal haemostatic agent.
Hedner U
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
[TBL] [Abstract][Full Text] [Related]
22. Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.
Puetz J
Drug Des Devel Ther; 2010 Jul; 4():127-37. PubMed ID: 20689699
[TBL] [Abstract][Full Text] [Related]
23. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
Hedner U
Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots.
Dargaud Y; Prevost C; Lienhart A; Claude Bordet J; Negrier C
Haemophilia; 2011 Nov; 17(6):957-61. PubMed ID: 21453422
[TBL] [Abstract][Full Text] [Related]
25. In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays.
Lund J; Jensen K; Burnier L; Ezban M
J Thromb Haemost; 2023 Jun; 21(6):1493-1502. PubMed ID: 37037699
[TBL] [Abstract][Full Text] [Related]
26. Recombinant activated factor VII: 30 years of research and innovation.
Hedner U
Blood Rev; 2015 Jun; 29 Suppl 1():S4-8. PubMed ID: 26073368
[TBL] [Abstract][Full Text] [Related]
27. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia.
He S; Ekman GJ; Hedner U
J Thromb Haemost; 2005 Feb; 3(2):272-9. PubMed ID: 15670032
[TBL] [Abstract][Full Text] [Related]
28. Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
Weeterings C; Lisman T; de Groot PG
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S12-5. PubMed ID: 18544417
[TBL] [Abstract][Full Text] [Related]
29. Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI.
Livnat T; Zivelin A; Martinowitz U; Salomon O; Seligsohn U
J Thromb Haemost; 2006 Jan; 4(1):192-200. PubMed ID: 16409469
[TBL] [Abstract][Full Text] [Related]
30. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
31. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
Hoffman M; Monroe DM; Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S61-5. PubMed ID: 9819030
[TBL] [Abstract][Full Text] [Related]
32. NovoSeven as a universal haemostatic agent.
Hedner U
Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S107-11. PubMed ID: 10850574
[TBL] [Abstract][Full Text] [Related]
33. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
34. Recombinant coagulation factor VIIa--from molecular to clinical aspects of a versatile haemostatic agent.
Persson E; Bolt G; Steenstrup TD; Ezban M
Thromb Res; 2010 Jun; 125(6):483-9. PubMed ID: 20006996
[TBL] [Abstract][Full Text] [Related]
35. Experiences with recombinant FVIIa in the emergency treatment of patients with autoimmune thrombocytopenia: a review of the literature.
Salama A; Rieke M; Kiesewetter H; von Depka M
Ann Hematol; 2009 Jan; 88(1):11-5. PubMed ID: 18787824
[TBL] [Abstract][Full Text] [Related]
36. High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
Wolberg AS; Allen GA; Monroe DM; Hedner U; Roberts HR; Hoffman M
Br J Haematol; 2005 Dec; 131(5):645-55. PubMed ID: 16351642
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of using recombinant factor VIIa in continuous infusion.
Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
[TBL] [Abstract][Full Text] [Related]
38. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
39. Recombinant factor VIIa (NovoSeven) as a hemostatic agent.
Hedner U
Dis Mon; 2003 Jan; 49(1):39-48. PubMed ID: 12525827
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.
Keshava S; Pendurthi UR; Esmon CT; Rao LVM
J Thromb Haemost; 2020 Aug; 18(8):1911-1921. PubMed ID: 32359012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
